Ocrelizumab for treating primary progressive multiple sclerosis
Technology appraisal guidance
Reference number: TA585
Published:
The final guidance for this appraisal will not be published on the website on 31st October 2018 as previously planned, as the appraisal has been paused while commercial discussions between the company and NHS England are taking place.